Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site-Reference-Cited by-同舟云学术

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site

Published:2017-07-31 Issue:11 Volume:31 Page:2388-2397
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hadzijusufovic E^ORCID,Albrecht-Schgoer K,Huber K^ORCID,Hoermann G,Grebien F^ORCID,Eisenwort G,Schgoer W,Herndlhofer S,Kaun C,Theurl M,Sperr W R,Rix U^ORCID,Sadovnik I,Jilma B,Schernthaner G H,Wojta J,Wolf D,Superti-Furga G^ORCID,Kirchmair R,Valent P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu2017245.pdf

Reference44 articles.

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–172.

2. Rowley JD . Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293.

3. Sattler M, Griffin JD . Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003; 40: 4–10.

4. Druker BJ . Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002; 21: 8541–8546.

5. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies;Hematology, Transfusion and Cell Therapy;2024-08

2. The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling;Molecular and Cellular Biochemistry;2024-07-15

3. Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score;Cardio-Oncology;2024-07-15

4. Review on cerebral malaria—Pathogenesis and role of EphA2 receptor in maintaining blood brain barrier integrity;Health Sciences Review;2024-06

5. Endothelial function in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors is not related to cardiovascular risk assessed by SCORE2 algorithm;Polish Archives of Internal Medicine;2024-04-03